This will be recognised as a landmark study, as it is the first to demonstrate a clear improvement in LCI in response to a recognised CF treatment in a population with normal spirometry results. The study is well designed and, in addition, the mass spectrometer-based sulfur hexafluoride ($SF_6$) MBW hardware and software is identical to that employed in numerous previous studies, and consistent with recent taskforce recommendations for this technique. The researchers could be criticised for not employing a control group, and also for not paying sufficient attention to the baseline variability of their outcome measures when interpreting the effect of their intervention; however, both are minor criticisms.

There are still challenges ahead for researchers intending to utilise LCI as an outcome measure in early CF. Long-term prospective longitudinal studies tracking LCI from infancy into adulthood are required, but data collection for such studies is inevitably lengthy and complex. Ultimately it will be necessary to demonstrate that children with CF managed with regular LCI monitoring have better outcomes than peers monitored by more conventional methods. In parallel, clinicians will expect that manufacturers develop MBW systems that are cheaper and more robust than the current home-built systems, and validated to the same standards. This author is not aware of any commercially available system that currently meets these standards, but it is possible to report two developments. One is a system built around a modified ultrasonic flowmeter and also for not employing a control group, their intervention; however, both are minor criticisms.

The second is a modified ultrasonic flowmeter system developed by a German group, and currently employed in a German multicentre trial. Both have been validated against the mass spectrometer system developed by Gustafsson et al.12 and show great promise, at least for LCI measurement in preschool children and above. At present the researchers’ modifications have not been commercialised by the manufacturers, but there is potential for the future.

Competing interests None.

Provenance and peer review Commissioned, not externally peer reviewed.


REFERENCES


Effects of steroid therapy on inflammatory cell subtypes in asthma

Louis-Philippe Boulet

Asthma is a chronic condition that usually develops after environmental exposures in genetically predisposed individuals. It is considered an inflammatory disease leading to airway structural changes (remodelling), both of these processes being involved in the development of airway hyper-responsiveness (AHR) and variable airway obstruction. When inflammation and remodelling increase to a sufficient degree, symptomatic asthma occurs.

Although asthma has been recognised for a very long time as a heterogeneous condition, recent efforts have been devoted to better characterising its various phenotypes. The term ‘phenotype’ refers to ‘a set of observable characteristics of an individual or group resulting from the interaction of its genotype with its environment’. Although these phenotypes may overlap or possibly vary over time, their characterisation may help to identify the predominant mechanisms involved and specific patterns of clinical presentation, predict clinical outcomes and may guide treatment. There is still, however, a lack of data in this field.
Various classification systems have been proposed for asthma phenotypes. Currently, these phenotypes are usually defined according to their inducers, physiological characteristics, clinical features or—particularly since the development of non-invasive measures of airway inflammation—by their inflammatory characteristics. The major categories of airway inflammatory phenotypes identified in subjects with asthma are the eosinophilic and non-eosinophilic types, with the latter including neutrophilic and pauci-granulocytic subtypes. A mixed form also exists in which both eosinophils and neutrophils are increased. These inflammatory phenotypes can be observed in children as well as in adults.

A frequently encountered phenotype of asthma is the eosinophilic type. It is associated with allergic or occupational asthma, steroid withdrawal, aspirin intolerance/nasal polyps and a subset of severe asthma. An increase in airway neutrophils has been observed in subgroups of individuals with occupational or severe asthma, smokers, elderly patients, in the presence of gastro-oesophageal reflux, following respiratory infections or endotoxin exposure, acute exacerbations and intense exercise. However, as neutrophils are present in the sputum of normal subjects and in a number of respiratory conditions, the criteria to ascertain their role should ideally include an increase in the total number of cells, a high viability of the sample and the percentage of neutrophils compared with normal values.

In a recent study, 44% of patients were found to have the eosinophilic phenotype, 31% had the paucigranulocytic phenotype, and the neutrophilic or mixed granulocytic subtypes were each found in 13%. Subjects with purely eosinophilic asthma had the most pronounced AHR to mannitol, while the lowest degree of AHR was observed in subjects with neutrophilic asthma. In this issue of Thorax, Cowan et al expand our understanding of asthma inflammatory phenotypes by providing data on their prevalence (see page 384). The investigators not only found a lower prevalence of the neutrophilic phenotype in patients with asthma compared with that noted above and previously reported, but they also found that this pattern was absent after corticosteroid withdrawal in non-smoking patients who did not have respiratory infection. Furthermore, this study confirms the influence of inhaled corticosteroids on the pattern of airway inflammation, not only being associated with a decrease in eosinophils but also with an increase in sputum neutrophils.

Cowan et al report a high prevalence of sputum eosinophilia following corticosteroid withdrawal, 70% of patients experiencing a loss of control after being weaned off corticosteroids. This last observation suggests that these patients were in need of such medication because of an underlying active inflammatory process manifested by an increased number of airway eosinophils. This is also supported by the clinical improvement in asthma with fluticasone. In addition, this study confirms the excellent clinical response to corticosteroids in patients with the eosinophilic inflammatory phenotype. Perhaps more importantly, as previously suggested, it shows that benefits could also be observed in patients without obvious airway eosinophilia.

With respect to the determination of asthma phenotypes, it has become obvious that assessment of airway inflammatory patterns is influenced by the use of medications such as corticosteroids. It may be difficult to differentiate the true inflammatory cell phenotype from the effects of the current corticosteroid treatment, mechanisms related to the severity or type of asthma and environmental exposures. In the report by Cowan et al, inhaled corticosteroid treatment with a high dose of fluticasone was associated with a significant increase in airway neutrophils, although only of about 10%. However, there may be a dose effect with regard to this influence on sputum neutrophil, and lower doses are likely to induce a smaller or no increase. There is also a possibility that patients with milder asthma not requiring corticosteroids or on a very low dose of inhaled corticosteroid could more frequently have a neutrophil phenotype, although this is probably to a large extent determined by environmental exposures, respiratory infections and age. In this regard, it is possible that the relatively unpolluted air in New Zealand is associated with lower numbers of airway neutrophils while in more polluted areas this phenotype could be more prevalent. As an example, a previous study examining the effects of short-term exposure to diesel traffic in people with asthma in a large city urban roadside environment showed an increase in biomarkers of neutrophilic inflammation, changes most consistently associated with exposure to ultrafine particles and elemental carbon. In the study by Cowan et al, as expected, forced expiratory volume in 1 s was the best predictor of increased airflow with treatment in both eosinophilic and non-eosinophilic asthma. The observation that the fraction of exhaled nitric oxide (Feno) can predict corticosteroid response in non-eosinophilic asthma is, however, surprising as Feno is considered to be a surrogate marker for airway eosinophilia. This may suggest that eosinophils are present in the airway wall or that other types of inflammatory airway processes responding to corticosteroids are reflected by Feno levels. Hence, Feno may be a better predictor of corticosteroid response than airway eosinophilia in this population.

With regard to the methods and choice of key measures used by Cowan et al, it is unlikely that the choice of cut-off points of ≥2% for eosinophils and ≥61% for neutrophils explains the results reported. These have been shown to discriminate adequately between these phenotypes, even taking into account possible environmental influences although, as already mentioned, there is a possible influence of environmental exposures on ‘normal’ values in a given area. It is also unlikely that the results would differ if whole sputum samples were analysed instead of selected plugs as the proportion of cells is similar. The absence of a placebo-controlled design could be considered a potential weakness of this study but such design, as mentioned by the authors, raises ethical issues in patients with asthma exacerbations, while the data obtained seem sufficiently robust to support the study conclusions. Finally, attraction, activation and survival of granulocytes in the airways are very dynamic processes and we should recognize that a single time-point sputum analysis provides a somewhat limited view of such a dynamic process.

In the report by Cowan et al, 31% of patients had pauci-granulocytic asthma. This pattern may be due to the presence of minimal or no airway inflammation at the time of measurement in patients with airway structural changes, possibly explaining the persistent changes in airway function. Porsbjerg et al reported that such patients had elevated levels of exhaled NO and AHR to mannitol, indicating increased disease activity compared with the neutrophilic group which had a low degree of AHR to mannitol and normal Feno levels. A possible benefit of corticosteroids in this group is supported by the findings of Cowan et al.
Further research should be conducted on inflammatory asthma phenotypes and their clinical relevance. In this regard, treatments targeting granulocytes such as mepolizumab for eosinophils or those antagonising neutrophilic responses will contribute to an understanding of their role in the clinical expression of asthma and how best to treat these conditions.

In conclusion, the report by Cowan and colleagues sheds more light on the prevalence of the various asthma phenotypes, particularly after corticosteroid withdrawal. The study shows that corticosteroids may increase neutrophil cell counts in induced sputum. It also suggests that, although baseline eosinophilia is a good predictor of the corticosteroid response, patients with no sputum eosinophilia may also show an improvement in their asthma with this treatment, particularly if they have increased Fevo levels. Further research should be done on how these phenotypes evolve over time, particularly with regard to environmental exposures and medication use. Their influence on clinical outcomes and response to treatments should also be further examined. Phenotyping by the inflammatory cell type provides an opportunity to better target asthma therapy, but how to assess such phenotype should be done using rigorous methods and the effects of corticosteroid use, smoking and environmental exposures should be taken into account in the interpretation of these data.

Competing interests None.

Provenance and peer review Commissioned; not externally peer reviewed.

Thorax 2010;65:374–376. doi:10.1136/thx.2009.131391

REFERENCES


376 Thorax May 2010 Vol 65 No 5

Thorax: first published as 10.1136/thx.2009.131391 on 30 April 2010. Downloaded from http://thorax.bmj.com on April 14, 2022 by guest. Protected by copyright.